Xcellerex Initiates Phase I Clinical Trial of Yellow Fever Vaccine
News Jan 13, 2010
Xcellerex, Inc. has announced that it has initiated a Phase I clinical trial of XRX-001, a novel, prophylactic vaccine against yellow fever, a tropical virus disease that is often fatal. The company is developing the vaccine to prevent yellow fever in persons traveling to tropical countries where yellow fever is endemic. The only currently available yellow fever vaccine is an attenuated, live vaccine with rare but potentially serious adverse effects.
XRX-001 is an inactivated virus vaccine adsorbed to alum adjuvant. Because it is inactivated and non-replicating, it is anticipated to significantly reduce the risks of serious and fatal adverse events that are sometimes associated with the live yellow fever vaccine.
In addition, the absence of foreign proteins derived from hens’ eggs should also reduce the risk of allergic reactions and eliminate the need to exclude egg-allergic people from vaccination. In addition, Xcellerex believes that the XRX-001 vaccine should not be subject to the precautions and contraindications of the currently marketed live vaccine. These precautions and contraindications, which are all related to potential serious outcomes of replicating live virus infection, include age <9 months or >65 years, immune suppression due to thymectomy, HIV/AIDS, cancer, treatment with immunosuppressive medications or radiation, and pregnancy.
“The initiation of the Phase I clinical trial is a significant milestone for Xcellerex and is further validation of both our disposable manufacturing technology and business model.”
The double-blind, controlled Phase I trial will enroll 60 healthy subjects divided into three groups. Two groups of volunteers will receive two different dose levels of XRX-001 and the third will receive placebo. The primary objective of the trial is to evaluate the safety and tolerability of XRX-001 vaccine, and secondary objectives will assess the neutralizing antibody response - an accepted correlate of protective immunity to yellow fever.
In a second parallel trial, the Company will compare the antibody response in those receiving XRX-001 to travelers receiving the currently-marketed vaccine.
Synaptic Proteins May Be Starting Point for Dementia TreatmentNews
A new study has identified key proteins, located at the brain's synaptic connections, which may be viable targets for dementia treatment.READ MORE
Brian Berridge Set to Manage National Toxicology ProgramNews
The National Toxicology Program (NTP) has named Brian Berridge, D.V.M., Ph.D., as its new Associate Director. Berridge, formerly of GlaxoSmithKline, will oversee day-to-day operations as NTP coordinates toxicology research and testing across nine different federal agencies.READ MORE
Safety and Efficacy of MERS Treatment Confirmed in Phase I TrialNews
An experimental treatment developed from cattle plasma for Middle East respiratory syndrome (MERS) coronavirus infection shows broad potential, according to a small clinical trial. The treatment, SAB-301, was safe and well tolerated by healthy volunteers, with only minor reactions documented.READ MORE